Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are employed: 1) prophylaxis, where the aim is to prevent clinically meaningful bleeds through maintaining factor VIII (FVIII) levels, and 2) on-demand treatment, where drugs are utilized at the time of a significant bleed. Various similar FVIII replacement therapies are available (e.g., Takeda’s Advate, Sanofi’s Eloctate). However, some patients develop inhibitors (alloantibodies) that can reduce the effectiveness of FVIII replacement. The launch of Genentech’s novel subcutaneous therapy Hemlibra has impacted the hemophilia A +/- inhibitors markets in differing ways. In the noninhibitor space, compelling reasons exist for many hemophilia A patients to remain on FVIII replacement therapies. In contrast, Hemlibra has dramatically altered treatment dynamics in the inhibitor space and has spurred much discussion regarding its merits in the management of newly diagnosed inhibitor patients.

QUESTIONS ANSWERED

  • Are physicians more likely to begin a previously untreated hemophilia A patient on factor VIII replacement or Genentech’s Hemlibra, and what is the rationale behind their decision?
  • How do physicians initially manage newly diagnosed high-titer inhibitor patients? What percentage of Hemlibra inhibitor patients are considered to be poor responders?
  • What are the 2020 branded patient shares of agents like Takeda’s Adynovate, Bayer’s Kovaltry, and Novo Nordisk’s NovoSeven? What do physicians forecast Hemlibra’s patient share to be in 2022?
  • How do different product types compare in average weekly units / kg dosing and number of weekly infusions?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Current Treatment Physician Insights - Hemophilia A - US - April 2020

Author(s): Kerri Brown, M Pharm

Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.


Related Reports

Hemophilia | Landscape & Forecast | Disease Landscape & Forecast

DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and the hemophilia market size will increase....

View Details